U.S. markets closed

Evaxion Biotech A/S (EVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.16+0.31 (+4.53%)
At close: 4:00PM EDT

7.16 0.00 (0.00%)
After hours: 4:01PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close6.85
Open6.70
Bid6.84 x 1200
Ask7.16 x 900
Day's Range6.57 - 7.16
52 Week Range5.16 - 10.34
Volume114,529
Avg. Volume142,896
Market Cap137.463M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
    GlobeNewswire

    Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy

    COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Jens Kringelum, PhD, Evaxion’s Director in Genomic Immuno-Oncology, at the 4th Neoantigen Summit Europe, being held virtually April 20-22, focusing on “AI in personalized cancer medicine”. The presentation described Evaxion’s recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-MHC (pMHC) complex stability. The work, previously reported in Nature Communications, December 9, 2020, outlines data on the thermostability of pMHC, the biological context for antigen processing. The paper explains how this method can be used to generate new data to train AI models for prediction of T-cell epitopes, and demonstrates how this appears to be a significant improvement over AI models trained on traditional mass spectrometry ligand data. The data have already proved valuable in enabling Evaxion’s artificial neural networks to more readily predict the immunological behavior of certain peptide epitopes. Lars Wegner, CEO of Evaxion, said: “This exciting research is an important advancement in how we at Evaxion can train AI systems to make drug development more efficient. In particular, we believe the data indicates how the use of pMHC thermostability can be used to train an improved model for the prediction of peptide immunogenicity, specifically of cancer neoepitopes. This is particularly relevant for Evaxion’s PIONEERTM, our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies.” PIONEER uses sophisticated algorithms to identify and select tumor-specific mutations that we believe are most likely to generate a de novo T-cell activation and anti-tumor immune response. These tumor-specific mutations, termed neoepitopes, are incorporated into patient-specific immunotherapies. Evaxion is continuously improving the performance of its PIONEER platform in selecting putative neoepitopes by modifying aspects of the underlying algorithms and through the development of novel methods for data generation. Although the stability of pMHC is known to be important, current assays assess this interaction only for a single peptide at a time and in isolation and not in the context of natural antigen processing and presentation. We believe this new method provides a comprehensive and unbiased measure of pMHC stability for thousands of individual ligands detected simultaneously by mass spectrometry. This allows rapid assessment of intra-allelic and inter-allelic differences in pMHC stability and shows profiles of stability that are broader than previously appreciated, facilitating the training of the new model. This assay can be applied to any cells bearing MHC or MHC-like molecules, offering insight into not only the endogenous immunopeptidome, but also that of neoepitopes and pathogen-derived sequences. About EvaxionEvaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Evaxion has developed its AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so the Company can harness its powers through novel immunotherapies. Evaxion’s scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. For more information EvaxionLifeSci Advisors LLCGlenn S. VraniakMary-Ann ChangChief Financial OfficerManaging Directorgvr@evaxion-biotech.commchang@lifesciadvisors.com+1 (513) 476-2669+44 7483 284 853 Source: Evaxion Biotech Forward-looking statement This announcement may contain certain forward-looking statements, including relating to the terms of the proposed offering and the completion of the proposed offering. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; risks associated with the cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

  • Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
    GlobeNewswire

    Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

    Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 millionClinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update. Lars Wegner, CEO of Evaxion, said: “Evaxion made outstanding progress in 2020 in redefining the immunotherapy discovery process through our AI platform technologies, despite the complications caused by the COVID-19 pandemic. We are very pleased with the successful initial public offering on U.S. Nasdaq, concluded in February 2021, which raised gross proceeds of $30 million and positions Evaxion for further progress with our patient-specific cancer immunotherapies.” “In 2020, we initiated a Phase 1/2a clinical trial of the adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. Both this study and our Phase 1/2a trial with EVX-01 remain on track and our other product candidates – EVX-03 for multiple cancer indications and EVX-B1, a vaccine for prevention of S. aureus – are progressing well through preclinical development.” “Financially, Evaxion is in a strong position with cash and cash equivalents of $5.8 million at December 31, 2020, to which we have now added the proceeds from our IPO. This provides funding to advance our four product candidates into 2022, covering a number of key expected milestones. These include Phase 1/2a data on EVX-01 and EVX-02 expected in late Q2 2021 and filing for approval of a clinical trial of EVX-03 in multiple cancers in the second half of the year.” Operational and Business Highlights in 2020 Dosed first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 in combination with checkpoint inhibitorsAppointed Marianne Søgaard, previously an attorney practicing technology law, including processes to acquire technology solutions, and commercial law, as Chairwoman of the Board of DirectorsLaunched new AI powered platform, RAVEN, to enable faster response to emerging viral pandemicsPartnered with SB3000 for rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technologyPublication of an article in Nature Communications showing how deep data on immune complex stability could optimize immunotherapy in cancer Events after the Reporting Period Closed U.S. initial public offering of 3,000,000 American Depositary Shares at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before deducting underwriting fees and commissions and other offering expenses, were $30 million.The shares began trading on the Nasdaq Capital Market on February 5, 2021 under the ticker symbol “EVAX”.Opened new corporate headquarters and research laboratory facility located in the DTU Science Park in Hoersholm near Copenhagen, Denmark. Expected milestones in 2021 Phase 1/2a data on EVX-01 in metastatic melanoma - Q2 2021Phase 1/2a data on EVX-02 in adjuvant melanoma - Q2 2021Regulatory filing for clinical trial of EVX-03 in multiple cancers - H2 2021 Fourth Quarter and Full Year 2020 Financial Results Cash position: As of December 31, 2020, cash and cash equivalents were $5.8 million compared to $9.6 million as of December 31, 2019. On February 9, 2021, we closed our recent IPO raising net proceeds of $27.9 million after underwriting discounts and commissions.Research and Development expenses were $10.9 million for the year ended December 31, 2020, compared to $8.2 million for the same period in 2019. The increase of $2.7 million was primarily related to increased spending, net of grant income, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased due to higher headcount.General and Administrative expenses were $5.7 million for the year ended December 31, 2020, compared to $2.6 million for the same period in 2019. The increase of $3.1 million was primarily related to increased employee-related costs due to increased headcount and increases in overhead and professional fees related to the expansion of our corporate function for our initial public offering.Net loss was $15.0 million for the year ended December 31, 2020 or ($0.97) loss per basic and diluted share, compared to $11.2 million, or ($0.81) loss per basic and diluted share, for the same period in 2019. Guidance Evaxion’s operating plan extends its cash runway into 2022. Webcast and Conference Call Evaxion will host a webcast and conference call today, April 6, 2021, at 8.30 a.m. EDT. To access dial-in details for the conference call, please use the following link:https://www.incommglobalevents.com/registration/client/7148/evaxion-biotech-q4-and-full-year-2020-earnings-call/ Alternatively to access the webcast, please use the following link:https://event.on24.com/wcc/r/3083146/DF0AB39A39342E036D397705A664556F About Evaxion Evaxion Biotech A/S is an AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Evaxion has developed its AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so the Company can harness its powers through novel immunotherapies. Evaxion’s scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients. For more information Evaxion Biotech A/S LifeSci Advisors LLCGlenn S. Vraniak Mary-Ann ChangChief Financial Officer Managing Directorgvr@evaxion-biotech.com mchang@lifesciadvisors.com+1 (513) 476-2669 +44 7483 284 853 Source: Evaxion Biotech Forward-looking statement This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s prospectus filed on February 5, 2021 and the Company’s current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Evaxion Biotech A/SConsolidated Statements of Financial Position Data (Unaudited)(USD in thousands) December 31, 2020 2019 Cash and cash equivalents $ 5,834 $ 9,559 Total assets 11,965 11,084 Total liabilities 4,927 1,722 Share capital 2,648 2,481 Other reserves 31,669 22,693 Accumulated deficit (27,279) (15,812) Total equity 7,038 9,362 Total liabilities and equity$11,965 $11,084 Evaxion Biotech A/SConsolidated Statements of Comprehensive Loss Data (Unaudited)(USD in thousands, except per share data) Year Ended December 31, 2020 2019 Research and development expenses $ 10,902 $ 8,216 General and administrative expenses 5,666 2,647 Operating loss (16,568) (10,863) Finance income 216 65 Finance expenses (223) (1,222) Net loss before tax (16,575) (12,020) Income taxes 1,557 825 Net loss for the period $ (15,018) $ (11,195) Net loss attributable to equity holders of Evaxion Biotech A/S $ (15,018) $ (11,195) Loss per share – basic and diluted $ (0.97) $ (0.81) Number of shares used for calculation (basic and diluted) 15,434,758 13,892,314

  • Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6
    GlobeNewswire

    Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6

    COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it will present its full-year financial results for 2020 on April 6. Lars Wegner, CEO of Evaxion, and Glenn Vraniak, CFO, will host an earnings call on April 6 at 8.30 a.m. EDT. To access dial-in details for the conference call, please use the following link: https://www.incommglobalevents.com/registration/client/7148/evaxion-biotech-q4-and-full-year-2020-earnings-call/ Alternatively to access the webcast, please use the following link: https://event.on24.com/wcc/r/3083146/DF0AB39A39342E036D397705A664556F About EvaxionEvaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. For more information EvaxionLifeSci Advisors LLCGlenn S. VraniakMary-Ann ChangChief Financial OfficerManaging Directorgvr@evaxion-biotech.commchang@lifesciadvisors.com+1 (513) 476-2669+44 7483 284 853 Source: Evaxion Biotech Forward-looking statement This company announcement may contain certain forward-looking statements, including relating to the terms of the proposed offering and the completion of the proposed offering. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.